Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab + FOLFIRI followed by FOLFOX ± cetuximab in KRAS wild-type metastatic colorectal cancer
2009-014041-81Phase 2Terminated
- Sponsor
- GOIM
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by GOIM. Started Aug 2009; status: terminated.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-014041-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014041-81.